<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03265327</url>
  </required_header>
  <id_info>
    <org_study_id>22309</org_study_id>
    <nct_id>NCT03265327</nct_id>
  </id_info>
  <brief_title>Effect of an Oral Supplement Containing Omega-3 and Omega-6 on Dry Eye Symptoms</brief_title>
  <acronym>TURMERIC</acronym>
  <official_title>The Use of a Novel Oral Supplement Containing Omega-3 and Omega-6 Fatty Acids on Dry Eye Symptoms (TURMERIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nature's Way Canada</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Contact Lens Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nature's Way Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effectiveness of two oral supplements on the ocular signs and
      symptoms in symptomatic dry eye patients. Eligible participants will be given one of two oral
      supplements to take once a day for up to three months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI) score</measure>
    <time_frame>At screening</time_frame>
    <description>The OSDI is assessed on a scale of 0 and 100. A higher composite score indicates more severe dryness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI) score</measure>
    <time_frame>At 1 month</time_frame>
    <description>The OSDI is assessed on a scale of 0 and 100. A higher composite score indicates more severe dryness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI) score</measure>
    <time_frame>At 3 months</time_frame>
    <description>The OSDI is assessed on a scale of 0 and 100. A higher composite score indicates more severe dryness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom Assessment in Dry Eye (SANDE) questionnaire</measure>
    <time_frame>At screening</time_frame>
    <description>The Symptom Assessment in Dry Eye (SANDE) questionnaire is a dry eye questionnaire that asks participants to describe the frequency and severity of their dry eye symptoms using a visual analogue scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom Assessment in Dry Eye (SANDE) questionnaire</measure>
    <time_frame>At 1 month</time_frame>
    <description>The Symptom Assessment in Dry Eye (SANDE) questionnaire is a dry eye questionnaire that asks participants to describe the frequency and severity of their dry eye symptoms using a visual analogue scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom Assessment in Dry Eye (SANDE) questionnaire</measure>
    <time_frame>At 3 months</time_frame>
    <description>The Symptom Assessment in Dry Eye (SANDE) questionnaire is a dry eye questionnaire that asks participants to describe the frequency and severity of their dry eye symptoms using a visual analogue scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Schirmers test</measure>
    <time_frame>At screening</time_frame>
    <description>The small strip of paper is removed from the Schirmer test package, folded at one end, and is inserted into the outer corner of the participant's eyes. The participant is asked to close their eyes and wait for 5 minutes. After 5 minutes, the paper is removed and the length of which the paper strip is wetted is recorded in mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Schirmers test</measure>
    <time_frame>At 1 month</time_frame>
    <description>The small strip of paper is removed from the Schirmer test package, folded at one end, and is inserted into the outer corner of the participant's eyes. The participant is asked to close their eyes and wait for 5 minutes. After 5 minutes, the paper is removed and the length of which the paper strip is wetted is recorded in mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Schirmers test</measure>
    <time_frame>At 3 months</time_frame>
    <description>The small strip of paper is removed from the Schirmer test package, folded at one end, and is inserted into the outer corner of the participant's eyes. The participant is asked to close their eyes and wait for 5 minutes. After 5 minutes, the paper is removed and the length of which the paper strip is wetted is recorded in mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective non-invasive tear film stability (NIKBUT)</measure>
    <time_frame>At screening</time_frame>
    <description>Time taken for tear film breakup as measured objectively in seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective non-invasive tear film stability (NIKBUT)</measure>
    <time_frame>At 1 month</time_frame>
    <description>Time taken for tear film breakup as measured objectively in seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective non-invasive tear film stability (NIKBUT)</measure>
    <time_frame>At 3 months</time_frame>
    <description>Time taken for tear film breakup as measured objectively in seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-invasive tear break up time (NITBUT)</measure>
    <time_frame>At screening</time_frame>
    <description>Time taken for tear film breakup as measured by a study investigator in seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-invasive tear break up time (NITBUT)</measure>
    <time_frame>At 1 month</time_frame>
    <description>Time taken for tear film breakup as measured by a study investigator in seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-invasive tear break up time (NITBUT)</measure>
    <time_frame>At 3 months</time_frame>
    <description>Time taken for tear film breakup as measured by a study investigator in seconds.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Bulbar hyperemia after 3 months</measure>
    <time_frame>At screening, 1 month and 3 months</time_frame>
    <description>The redness of the bulbar conjunctiva of both eyes will be assessed in all four quadrants using the Efron scale (0-4, in 0.1 steps).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Limbal hyperemia after 3 months</measure>
    <time_frame>At screening, 1 month and 3 months</time_frame>
    <description>The redness of the limbal conjunctiva of both eyes will be assessed in all four quadrants using the Efron scale (0-4, in 0.1 steps).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tear meniscus height after 3 months</measure>
    <time_frame>At screening, 1 month and 3 months</time_frame>
    <description>Measurement of tear meniscus height in mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Meiboscore (Arita's scale) after 3 months</measure>
    <time_frame>At screening, 1 month and 3 months</time_frame>
    <description>Graded on 0-3 scale. Grade 0: no dropout, Grade 1: &lt; 1/3 total area dropout, Grade 2: 1/3 to 2/3 total area dropout, Grade 3: &gt; 2/3 total area dropout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual acuity after 3 months</measure>
    <time_frame>At screening, 1 month and 3 months</time_frame>
    <description>High contrast logMAR VA with computerized charts in high illumination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tear osmolarity after 3 months</measure>
    <time_frame>At screening and 3 months</time_frame>
    <description>Measure of the osmolarity of collected tears.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Omega-3 index after 3 months</measure>
    <time_frame>At screening and 3 months</time_frame>
    <description>Amount of EPA and DHA in erythrocytes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an oral supplement containing fish oil, evening primrose oil and borage oil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive an oral supplement containing coconut oil and light olive oil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral supplement containing omega-3 and omega-6</intervention_name>
    <description>An oral supplement containing omega-3 and omega-6</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral supplement containing coconut and olive oil</intervention_name>
    <description>An oral supplement containing coconut oil and olive oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is over 19 years of age and has full legal capacity to volunteer;

          2. Has read and signed an information consent letter;

          3. Is willing and anticipated to be able to comply with the daily intake of liquid oil
             supplements (one teaspoon per day for three months);

          4. Is willing and able to follow instructions and maintain the appointment schedule;

          5. Exhibit moderate ocular dryness symptoms, defined as:

               1. A score of ≥23 on the Ocular Surface Disease Index (OSDI, (Allergan Inc., Irvine,
                  CA)) questionnaire;

               2. Currently using ocular lubricating drops at least once per day for, at least, the
                  past 3 months;

        Exclusion Criteria:

          1. Is participating in any concurrent clinical or research study;

          2. Has any known active* ocular disease and/or infection;

          3. Currently wears, or has worn contact lenses in the past 3 months;

          4. Has sensitivity or an allergy to products that contain fish, soy, coconut oil or olive
             oil;

          5. Has a systemic condition that in the opinion of the investigator may affect a study
             outcome variable;

          6. Is using any systemic or topical medications (including topical corticosteroids/NSAIDs
             or glaucoma medications) that in the opinion of the investigator may affect a study
             outcome variable;

          7. Is currently taking, or has used, any omega-3 or omega-6 supplements in the last three
             months;

          8. Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;

          9. Is pregnant, lactating or planning a pregnancy at the time of enrolment;

         10. Is aphakic;

         11. Has undergone refractive error surgery;

         12. Is an employee of the Centre for Contact Lens Research;

         13. Has taken part in another (pharmaceutical) research study within the last 30 days;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jill Woods, MCOptom</last_name>
    <phone>519-888-4567</phone>
    <phone_ext>36743</phone_ext>
    <email>jwoods@uwaterloo.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Contact Lens Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Woods, MCOptom</last_name>
      <phone>519-888-4567</phone>
      <phone_ext>36743</phone_ext>
      <email>jwoods@uwaterloo.ca</email>
    </contact>
    <investigator>
      <last_name>Lyndon Jones, PhD, FCOptom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

